Bleximenib
Bleximenib is an oral experimental drug from Janssen that targets a protein interaction called menin-KMT2A. It’s being studied for acute myeloid leukemia (AML) and related leukemias in patients whose cancer cells have specific genetic changes: KMT2A rearrangements or NPM1 mutations. These alterations occur in about 40% of AML cases and help leukemic cells survive.
In preclinical studies, bleximenib showed strong potency and works by blocking the menin-KMT2A interaction, which lowers the activity of cancer-driving genes such as HOXA9 and MEIS1. This disruption pushes leukemia cells to mature and stop growing, while aiming to spare normal blood cells and reduce toxicity.
Clinically, the drug is in a Phase 1/2 first-in-human study for relapsed or refractory acute leukemia with these genetic changes. The trial uses a dose-escalation approach to find a safe and effective dose, with researchers also testing combinations to improve responses. Early results support exploring combinations with standard therapies. For example, combining bleximenib with venetoclax and azacitidine has shown encouraging activity and manageable safety, and another study tests it with intensive chemotherapy for newly diagnosed patients.
Safety looks manageable so far, though some patients experience serious neutropenia, which is common in AML trials. Differentiation syndrome, a known potential side effect of menin inhibitors, has been observed but is treatable. No significant heart rhythm problems have been linked to bleximenib in studies yet.
As of late 2025, bleximenib remains investigational and has not received regulatory approval. It is part of a broader effort to target the menin-KMT2A interaction, an area also explored by other drugs in development.
This page was last edited on 3 February 2026, at 13:17 (CET).